Compare Biocon Ltd with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs TORRENT PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON TORRENT PHARMA BIOCON /
TORRENT PHARMA
 
P/E (TTM) x 30.7 38.7 79.2% View Chart
P/BV x 4.0 8.4 47.1% View Chart
Dividend Yield % 0.2 0.7 34.3%  

Financials

 BIOCON    TORRENT PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
TORRENT PHARMA
Mar-19
BIOCON /
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs7071,964 36.0%   
Low Rs5541,245 44.5%   
Sales per share (Unadj.) Rs91.9453.4 20.3%  
Earnings per share (Unadj.) Rs16.725.8 64.8%  
Cash flow per share (Unadj.) Rs24.262.3 38.8%  
Dividends per share (Unadj.) Rs1.0017.00 5.9%  
Dividend yield (eoy) %0.21.1 15.0%  
Book value per share (Unadj.) Rs101.6279.2 36.4%  
Shares outstanding (eoy) m600.00169.22 354.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.93.5 193.9%   
Avg P/E ratio x37.762.2 60.6%  
P/CF ratio (eoy) x26.125.8 101.3%  
Price / Book Value ratio x6.25.7 108.0%  
Dividend payout %6.065.9 9.1%   
Avg Mkt Cap Rs m378,330271,513 139.3%   
No. of employees `0006.113.6 45.1%   
Total wages/salary Rs m11,65314,038 83.0%   
Avg. sales/employee Rs Th8,994.35,642.6 159.4%   
Avg. wages/employee Rs Th1,900.71,032.4 184.1%   
Avg. net profit/employee Rs Th1,635.3320.9 509.7%   
INCOME DATA
Net Sales Rs m55,14476,728 71.9%  
Other income Rs m1,444571 253.1%   
Total revenues Rs m56,58877,299 73.2%   
Gross profit Rs m15,88319,831 80.1%  
Depreciation Rs m4,4786,177 72.5%   
Interest Rs m7095,038 14.1%   
Profit before tax Rs m12,1409,187 132.1%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m2,1231,254 169.4%   
Profit after tax Rs m10,0264,363 229.8%  
Gross profit margin %28.825.8 111.4%  
Effective tax rate %17.513.6 128.2%   
Net profit margin %18.25.7 319.7%  
BALANCE SHEET DATA
Current assets Rs m48,22850,375 95.7%   
Current liabilities Rs m30,37651,653 58.8%   
Net working cap to sales %32.4-1.7 -1,943.9%  
Current ratio x1.61.0 162.8%  
Inventory Days Days6892 74.2%  
Debtors Days Days8668 125.2%  
Net fixed assets Rs m64,13083,648 76.7%   
Share capital Rs m3,000846 354.5%   
"Free" reserves Rs m57,98046,397 125.0%   
Net worth Rs m60,98047,244 129.1%   
Long term debt Rs m15,76639,129 40.3%   
Total assets Rs m121,924141,209 86.3%  
Interest coverage x18.12.8 641.8%   
Debt to equity ratio x0.30.8 31.2%  
Sales to assets ratio x0.50.5 83.2%   
Return on assets %8.86.7 132.3%  
Return on equity %16.49.2 178.0%  
Return on capital %16.812.3 135.8%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50622,103 70.2%   
Fx outflow Rs m10,3995,522 188.3%   
Net fx Rs m5,10716,581 30.8%   
CASH FLOW
From Operations Rs m11,54617,981 64.2%  
From Investments Rs m-7,138-2,413 295.8%  
From Financial Activity Rs m-2,417-13,145 18.4%  
Net Cashflow Rs m2,1032,380 88.4%  

Share Holding

Indian Promoters % 40.4 71.5 56.5%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 7.0 119.7%  
FIIs % 10.7 12.6 84.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 8.8 226.1%  
Shareholders   109,995 26,511 414.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  SANOFI INDIA  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 466 Points Higher; Energy, Auto and Realty Stocks Rally(Closing)

Indian share markets extended gains as the session progressed and ended on a strong note, driven by automobile stocks and index heavyweight Reliance Industries.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jul 6, 2020 03:33 PM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS